Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

About this update from Anavex Life Sciences Corp.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will  host a conference call at 4:00 PM ET on Wednesday, September 9, 2026 , during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company's clinical development strategy and priorities. Anavex Investor Call Information: The Company is now current on its financial reporting obligations with the Securities and Exchange Commission and, on September 2, 2026, officially regained compliance with NASDAQ listing rules as a result of filing its outstanding Form 10-Qs for the second and third fiscal quarters for 2026. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com . Investor Relations & Media Contact: SCR Partners, LLC Alex Arzeno Tel: 203-550-3972 Email: [email protected] Tripp Sullivan Tel: 615-942-7077 Email: [email protected] Company Contact: Sandra Boenisch Principal Financial Officer Anavex Life Sciences Corp. Tel: 1-844-689-3939 Email: [email protected]

View stock analysis, news, and events for Anavex Life Sciences Corp.